The risk-benefit profile remains unclear. For post-menopausal women with severe, progressive osteoporosis who have exhausted or cannot tolerate conventional therapy (bisphosphonates, hormone therapy), exploratory cell therapy may be considered a lower-risk alternative to no intervention, provided trial data and informed consent are transparent. For mild-to-moderate cases, conventional agents remain first-line.
Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material. Osteoporosis occurs when remodelling becomes imbalanced, with too much removal and insufficient replacement, leaving a porous, fragile architecture vulnerable to fracture. Placental mesenchymal stem cells have attracted research interest because they can differentiate into osteoblasts, potentially helping restore bone-forming capacity. The mechanism appears to involve both direct cellular replacement of bone-building cells and the release of signalling molecules (cytokines) that shift the remodelling ratio back toward deposition. Early-stage trials are exploring whether cell therapy can slow or partially reverse the density loss that typically accelerates after oestrogen withdrawal in post-menopausal women, though robust efficacy data remain limited.
Bin ich ein Kandidat? → · Osteoporosis & Bone Health: full overview → · Osteoporose und Knochengesundheit Kosten → · Cost →
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung